Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Breast Neoplasms 77Carcinoma, Non-Small-Cell Lung 64Lung Neoplasms 31Hodgkin Disease 13Lymphoma 11Neoplasm Metastasis 10Recurrence 8Lymphoma, Non-Hodgkin 8Prostatic Neoplasms 7Neoplasms 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 5Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Mesothelioma, Malignant 4Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms, Male 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Burkitt Lymphoma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

Carboplatin 27Paclitaxel 23Cisplatin 22Gemcitabine 17pembrolizumab 15Fluorouracil 9Pemetrexed 8Everolimus 8Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Radiotherapy 7130-nm albumin-bound paclitaxel 7Sorafenib 6Nivolumab 6Bevacizumab 6Axitinib 6epothilone B 5Sunitinib 5Radiation 5Panitumumab 5Cyclophosphamide 5trebananib 4reolysin 4padeliporfin 4lenvatinib 4Irinotecan 4Gefitinib 4vosaroxin 3volociximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma × Vinorelbine × Clear all
NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed
178 enrolled 37 charts
Breast

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT01109524 2015-12-24

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
72 enrolled 15 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡